Kynam Capital Management LP 13D and 13G filings for Celldex Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-05-15 11:48 am Purchase |
2025-03-31 | 13G | Celldex Therapeutics, Inc. CLDX |
Kynam Capital Management LP | 6,500,000 9.790% |
1,435,793 (+28.35%) |
Filing |
| 2025-02-14 5:16 pm Purchase |
2024-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
Kynam Capital Management LP | 5,064,207 7.630% |
2,058,303 (+68.48%) |
Filing |
| 2024-02-14 12:52 pm Purchase |
2023-12-31 | 13G | Celldex Therapeutics, Inc. CLDX |
Kynam Capital Management LP | 3,005,904 5.500% |
3,005,904 (New Position) |
Filing |